Literature DB >> 33420680

Hippocampal Degeneration and Behavioral Impairment During Alzheimer-Like Pathogenesis Involves Glutamate Excitotoxicity.

Olayemi Joseph Olajide1,2, Ismail Tayo Gbadamosi3,4, Emmanuel Olusola Yawson3,5, Tolulope Arogundade3,6, Folashade Susan Lewu3, Kehinde Yomi Ogunrinola3,7, Oluwaseun Olaniyi Adigun3, Olawande Bamisi3,8, Ezra Lambe3, Leviticus Ogbenevurinrin Arietarhire3, Olushola Oladapo Oluyomi3, Olumayowa Kolawole Idowu3, Rukayat Kareem3, Nnaemeka Tobechukwu Asogwa4,9, Philip Adeyemi Adeniyi10.   

Abstract

The hallmarks of Alzheimer's disease (AD) pathology include senile plaques accumulation and neurofibrillary tangles, which is thought to underlie synaptic failure. Recent evidence however supports that synaptic failure in AD may instead be instigated by enhanced N-methyl-D-aspartate (NMDA) activity, via a reciprocal relationship between soluble amyloid-β (Aβ) accumulation and increased glutamate agonist. While previous studies have shown Aβ-mediated alterations to the glutamatergic system during AD, the underlying etiology of excitotoxic glutamate-induced changes has not been explored. Here, we investigated the acute effects of stereotaxic dentate gyrus (DG) glutamate injection on behavior and molecular expression of specific proteins and neurochemicals modulating hippocampal functions. Dependence of glutamate-mediated effects on NMDA receptor (NMDAR) hyperactivation was tested using NMDARs antagonist memantine. DG of Wistar rats (12-weeks-old) were bilaterally microinjected with glutamate (500 mM) with or without daily intraperitoneal (i.p.) memantine injection (20 mg/kg) for 14 days, while controls received either intrahippocampal/i.p. PBS or i.p. memantine. Behavioral characterization in open field and Y-maze revealed that glutamate evoked anxiogenic responses and perturbed spatial memory were inhibited by memantine. In glutamate-treated rats, increased NO expression was accompanied by marked reduction in profiles of glutathione-s-transferase and glutathione peroxidase. Similarly, glutamate-mediated increase in acetylcholinesterase expression corroborated downregulation of synaptophysin and PSD-95, coupled with initiation of reactive astrogliosis (GFAP). While neurofilament immunolocalization/immunoexpression was unperturbed, we found glutamate-mediated reduction in neurogenic markers Ki67 and PCNA immunoexpression, with a decrease in NR2B protein expression, whereas mGluR1 remains unchanged. In addition, increased expression of apoptotic regulatory proteins p53 and Bax was seen in glutamate infused rats, corroborating chromatolytic degeneration of granule neurons in the DG. Interestingly, memantine abrogated most of the degenerative changes associated with glutamate excitotoxicity in this study. Taken together, our findings causally link acute glutamate dyshomeostasis in the DG with development of AD-related behavioral impairment and molecular neurodegeneration.

Entities:  

Keywords:  Alzheimer’s disease; Dentate gyrus; Excitotoxicity; Glutamate; Memantine; NMDAR

Year:  2021        PMID: 33420680     DOI: 10.1007/s12031-020-01747-w

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  52 in total

1.  Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses.

Authors:  Claudia G Almeida; Davide Tampellini; Reisuke H Takahashi; Paul Greengard; Michael T Lin; Eric M Snyder; Gunnar K Gouras
Journal:  Neurobiol Dis       Date:  2005-11       Impact factor: 5.996

2.  Folic Acid potentiates the effect of memantine on spatial learning and neuronal protection in an Alzheimer's disease transgenic model.

Authors:  Ta-Fu Chen; Rwei-Fen S Huang; Sey-En Lin; Jyh-Feng Lu; Ming-Chi Tang; Ming-Jang Chiu
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

3.  Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents.

Authors:  C Chipana; I Torres; J Camarasa; D Pubill; E Escubedo
Journal:  Neuropharmacology       Date:  2008-04-09       Impact factor: 5.250

Review 4.  The glutamatergic system and Alzheimer's disease: therapeutic implications.

Authors:  D Allan Butterfield; Chava B Pocernich
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 5.  Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity.

Authors:  Mark Arundine; Michael Tymianski
Journal:  Cell Calcium       Date:  2003 Oct-Nov       Impact factor: 6.817

6.  Calcium signalling and Alzheimer's disease.

Authors:  Michael J Berridge
Journal:  Neurochem Res       Date:  2010-12-24       Impact factor: 3.996

7.  Neuronal-glial Interactions Define the Role of Nitric Oxide in Neural Functional Processes.

Authors:  Antonio Contestabile; Barbara Monti; Elisabetta Polazzi
Journal:  Curr Neuropharmacol       Date:  2012-12       Impact factor: 7.363

8.  Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease.

Authors:  Manuel Buttini; Eliezer Masliah; Robin Barbour; Henry Grajeda; Ruth Motter; Kelly Johnson-Wood; Karen Khan; Peter Seubert; Stephen Freedman; Dale Schenk; Dora Games
Journal:  J Neurosci       Date:  2005-10-05       Impact factor: 6.709

9.  Characterization of the proteome, diseases and evolution of the human postsynaptic density.

Authors:  Alex Bayés; Louie N van de Lagemaat; Mark O Collins; Mike D R Croning; Ian R Whittle; Jyoti S Choudhary; Seth G N Grant
Journal:  Nat Neurosci       Date:  2010-12-19       Impact factor: 24.884

Review 10.  Elusive roles for reactive astrocytes in neurodegenerative diseases.

Authors:  Lucile Ben Haim; Maria-Angeles Carrillo-de Sauvage; Kelly Ceyzériat; Carole Escartin
Journal:  Front Cell Neurosci       Date:  2015-08-03       Impact factor: 5.505

View more
  8 in total

Review 1.  Potential mechanisms underlying lithium treatment for Alzheimer's disease and COVID-19.

Authors:  H-F Wei; S Anchipolovsky; R Vera; G Liang; D-M Chuang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2022-03       Impact factor: 3.784

Review 2.  Calcium Permeable-AMPA Receptors and Excitotoxicity in Neurological Disorders.

Authors:  Changyong Guo; Yao-Ying Ma
Journal:  Front Neural Circuits       Date:  2021-08-17       Impact factor: 3.342

3.  Transneuronal Degeneration in the Visual Pathway of Rats following Acute Retinal Ischemia/Reperfusion.

Authors:  Yanyan Fu; Tu Hu; Qianyue Zhang; Shuhan Meng; Ying Lu; Aiqun Xiang; Yewei Yin; Yuanjun Li; Jiayu Song; Dan Wen
Journal:  Dis Markers       Date:  2021-12-07       Impact factor: 3.434

Review 4.  Repurposed anti-cancer epidermal growth factor receptor inhibitors: mechanisms of neuroprotective effects in Alzheimer's disease.

Authors:  Heba M Mansour; Hala M Fawzy; Aiman S El-Khatib; Mahmoud M Khattab
Journal:  Neural Regen Res       Date:  2022-09       Impact factor: 5.135

5.  Epidermal Growth Factor Receptor Kinase Inhibitor Ameliorates β-Amyloid Oligomer-Induced Alzheimer Disease in Swiss Albino Mice.

Authors:  Jagadeesh Dhamodharan; Ganthimathy Sekhar; Arunachalam Muthuraman
Journal:  Molecules       Date:  2022-08-14       Impact factor: 4.927

6.  Cannabidiol Reduces Short- and Long-Term High Glutamate Release after Severe Traumatic Brain Injury and Improves Functional Recovery.

Authors:  Cindy Santiago-Castañeda; Saúl Huerta de la Cruz; Christopher Martínez-Aguirre; Sandra Adela Orozco-Suárez; Luisa Rocha
Journal:  Pharmaceutics       Date:  2022-08-02       Impact factor: 6.525

Review 7.  Effects of transcranial magnetic stimulation on neurobiological changes in Alzheimer's disease (Review).

Authors:  Shahid Bashir; Mohammad Uzair; Turki Abualait; Muhammad Arshad; Roaa A Khallaf; Asim Niaz; Ziyad Thani; Woo-Kyoung Yoo; Isaac Túnez; Asli Demirtas-Tatlidede; Sultan Ayoub Meo
Journal:  Mol Med Rep       Date:  2022-02-04       Impact factor: 2.952

Review 8.  The neurogenic niche in Alzheimer's disease.

Authors:  Connor M Wander; Juan Song
Journal:  Neurosci Lett       Date:  2021-07-13       Impact factor: 3.197

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.